We are live on ! Find out more
FRTX

Fresh Tracks Therapeutics, Inc. Common Stock

Delisted

FRTX was delisted on the 18th of December, 2023.

36 hedge funds and large institutions have $13.1M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

25% more capital invested

Capital invested by funds: $10.5M → $13.1M (+$2.62M)

16% less funds holding

Funds holding: 4336 (-7)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

Holders
36
Holders Change
-7
Holders Change %
-16.28%
% of All Funds
0.96%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
9
Reduced
4
Closed
15
Calls
$152K
Puts
Net Calls
+$152K
Net Calls Change
+$153K
Name Holding Trade Value Shares
Change
Change in
Stake
TRCT
51
Tower Research Capital (TRC)
New York
-$1K -1 Closed

FRTX Hedge Fund Activity: Q2 2016 in Review

36 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q2 2016, worth a combined $13.1M — up 25% from $10.5M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of FRTX and 9 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 9 added.

The largest buyer was Renaissance Technologies, adding an estimated $346K. The largest seller was Fidelity Investments, cutting an estimated $109K.

  • 36 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q2 2016, down from 43 in Q1 2016.
  • Funds reported $13.1M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q2 2016, up 25% quarter-over-quarter.
  • 9 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q2 2016 and 15 closed out, a net change of -6 holders.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q2 2016 was Renaissance Technologies, an estimated $346K added.
  • The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q2 2016 was Fidelity Investments, an estimated $109K sold.

Based on aggregated 13F filings for Q2 2016.